Should you be confident in argenx se(argx)?
Investment management company Baron Funds has released the second quarter of 2025 Baron Health Care Fund for investors. A copy of a letter can do so I downloaded it from here. The fund fell 5.06% (facilities stock) in the quarter against a challenging background in the broader health sector compared to a 6.19% decline in the Russell 3000 Healthcare Index (benchmark) and a 10.99% profit in the Russell 3000 Index (index). Plus, check out our top 5 holdings funds to find out the best picks of 2025.
In its second quarter, 2025 investor letter, Baron Healthcare Fund highlighted stocks such as Argenx SE (NASDAQ: ARGX). Argenx SE (NASDAQ: ARGX) designs and manufactures electrical, electronic and optical fiber connectors. Argenx SE (NASDAQ: ARGX)’s one-month return was 10.20%, and its shares have won 16.02% of its value over the past 52 weeks. On July 30, 2025, Argenx SE (NASDAQ:ARGX) shares closed at $598.89 per share, with a market capitalization of $3.6652 billion.
In its second quarter 2025 investor letter, the Baron Healthcare Fund stated the following regarding Argenx SE (NASDAQ: ARGX).
“Argenx se (NASDAQ: Argx is a biotech company best known for developing Vyvgart, the leading FCRN inhibitor for the treatment of autoimmune conditions. Stocks have declined after quarter sales fell below investors’ expectations due to a combination of seasonal factors (such as insurance approval). As a key treatment with long-term growth potential, Vyvgart expects to show an expanding range of autoantibody-driven autoimmune diseases.
Researchers at Lab Court, filled with scientific instruments and working with lab settings to develop new treatments for autoimmune diseases.
Argenx SE (Nasdaq: Argx) is not on our list 30 Most Popular Stocks of Hedge Funds. According to the database, the 54 hedge fund portfolio held Argenx SE (NASDAQ: ARGX) at the end of the first quarter of the last quarter. While acknowledging the potential of Argenx SE (NASDAQ: ARGX) as an investment, we believe certain AI stocks offer a greater reverse chance and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.